Published Date : 2025-Jun-20
Global Targeted Therapy represents a groundbreaking advancement in modern medicine—focusing on specific genes and proteins involved in the growth and survival of cancer cells. The global targeted therapy market is expanding rapidly due to rising cancer prevalence, increased demand for precision medicine, and growing R&D investments.
The market is projected to reach US$ 109.44 Billion by 2032, growing at a CAGR of 7.2%.
In this blog, we explore the top companies (established leaders + promising startups), regional, segmentation, competitive dynamics, trends, and emerging innovations shaping the future of this market.
Would you like me to add more details on specific companies or market trends? Let me know! CLICK HERE
Largest market share due to advanced healthcare infrastructure, strong R&D, and early drug approvals.
High adoption of precision medicine and immunotherapy in the U.S.
Rapid growth in countries like Germany, France, and the U.K.
Supportive regulatory policies and funding in oncology research.
Fastest-growing region led by China, India, and Japan.
Growing healthcare expenditure and patient pool.
M&A Activity: AbbVie acquired Allergan; Pfizer is expanding its oncology pipeline.
Pipeline Focus: Biologics and antibody-drug conjugates remain top areas of investment.
IP & Trials: Competition intensifies in late-stage clinical trials for rare and aggressive cancer types.
Rising cancer prevalence globally (especially breast, lung, and prostate).
Demand for personalized and less toxic treatments.
AI in drug discovery accelerating new therapy development.
Favorable regulatory pathways for orphan drugs and rare cancers.
Biotech collaborations between startups and pharma giants.
Bispecific antibodies targeting two cancer markers simultaneously.
mRNA-based platforms evolving post-COVID success.
CRISPR used in customizing targeted cancer treatments.
Liquid biopsy integration for better real-time therapy guidance.
Q1: What is targeted therapy in cancer treatment?
Answer: Targeted therapy uses drugs designed to "target" specific genetic mutations or proteins involved in cancer cell growth—minimizing damage to healthy cells.
Q2: Which cancers are most commonly treated with targeted therapy?
Answer: Breast cancer, lung cancer, colorectal cancer, melanoma, and leukemia are common cancers treated with targeted therapy.
Q3: How does targeted therapy differ from chemotherapy?
Answer: Unlike chemotherapy, which affects both healthy and cancerous cells, targeted therapy focuses only on specific cancer-causing molecules, reducing side effects.
Q4: What’s the projected market size of targeted therapy by 2025?
Answer: The global targeted therapy market is projected to exceed US$ 109.44 billion by 2032, growing at a CAGR of 7.2%.
Q5: Are startups important players in this market?
Answer: Yes. Startups like Blueprint Medicines and Relay Therapeutics are driving innovation in rare cancers and precision oncology.
IMIR Market Research is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including, Semiconductor, aerospace, Automation, Agriculture, Food & Beverages, Automotive, Chemicals and Materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports.
Contact Us: IMIR Market Research Pvt. Ltd.
Email: sales@intellectualmarketinsights.com
Call Us: +1 (814) 487 8486
